Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials.
Emmanuel S AntonarakisSumit K SubudhiChristopher M PieczonkaLawrence Ivan KarshDavid I QuinnJason M HafronHelen M WilfehrtMatthew HarmonNadeem A SheikhNeal D ShoreDaniel P PetrylakPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Median OS was consistent regardless of whether the agents were administered sequentially or concurrently, including after NDI update. Results suggest that sipuleucel-T induces an immunologic prime-boost effect after initial sipuleucel-T exposure, even when combined with ARTAs.